K
Krzysztof Jeziorski
Researcher at Curie Institute
Publications - 10
Citations - 1079
Krzysztof Jeziorski is an academic researcher from Curie Institute. The author has contributed to research in topics: Lapatinib & Capecitabine. The author has an hindex of 8, co-authored 10 publications receiving 960 citations. Previous affiliations of Krzysztof Jeziorski include University of Miami.
Papers
More filters
Journal ArticleDOI
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
J. Randolph Hecht,Yung-Jue Bang,Shukui K. Qin,Hyun Cheol Chung,Jianming Xu,Joon Oh Park,Krzysztof Jeziorski,Yaroslav Shparyk,Paulo M. Hoff,Alberto Sobrero,Pamela Salman,Jin Li,Svetlana A. Protsenko,Zev A. Wainberg,Marc Buyse,Karen Afenjar,Vincent Houe,Agathe Garcia,Tomomi Kaneko,Yingjie Huang,Saba Khan-Wasti,Sergio Santillana,Michael F. Press,Dennis J. Slamon +23 more
TL;DR: Addition of lapatinib to CapeOx did not increase OS in patients with HER2-amplified gastroesophageal adenocarcinoma, and no correlation was observed between HER2 immunohistochemistry status and survival.
Journal ArticleDOI
Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nolatrexed or Doxorubicin
Robert G. Gish,Camillo Porta,Lucian Lazar,Paul Ruff,Ronald Feld,Adina E. Croitoru,Lynn G. Feun,Krzysztof Jeziorski,John Charles Leighton,José Gallo,Gerard T. Kennealey +10 more
TL;DR: NOL showed minimal activity in this phase III trial and further exploration at this dose and schedule in HCC is not warranted.
Journal ArticleDOI
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.
J. Randolph Hecht,Yung-Jue Bang,Shukui Qin,Hyun Chul Chung,Jianming Xu,Joon Oh Park,Krzysztof Jeziorski,Yaroslav Shparyk,Paulo M. Hoff,Alberto Sobrero,Pamela Salman,Jin Li,Svetlana A. Protsenko,Marc Buyse,Karen Afenjar,Tomomi Kaneko,Allison Kemner,Sergio Santillana,Michael F. Press,Dennis J. Slamon +19 more
TL;DR: The addition of L to CapeOx did not reach its primary endpoint, though certain subgroups showed improvement, and the analysis of PFS censored by the time of subsequent anticancer therapy as per protocol showed a significant improvement.
Journal ArticleDOI
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial
Michel Ducreux,E. Van Cutsem,J.-L. Van Laethem,Thomas M. Gress,Krzysztof Jeziorski,Ph. Rougier,T. Wagener,O. Anak,Benoit Baron,Bernard Nordlinger +9 more
TL;DR: Cisplatin in combination with 5FU+FA showed a higher activity than HDFU, but was more toxic; these results are not sufficient to start a phase III trial.
Journal ArticleDOI
Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie
Manfred P. Lutz,Hansjochen Wilke,D.J. Theo Wagener,Udo Vanhoefer,Krzysztof Jeziorski,Susanna Hegewisch-Becker,Leopold Balleisen,Eric Joossens,Rob L. H. Jansen,Muriel Debois,U. Bethe,M. Praet,Jacques Wils,Eric Van Cutsem +13 more
TL;DR: In this article, a multicentric, randomized, two-stage phase II trial evaluated three simplified weekly infusional regimens of fluorouracil (FU) or FU plus folinic acid (FA) and cisplatin (Cis) with the aim to select a regimen for future phase III trials.